- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06771115
Fase 2a placebokontrollert studie av VTX3232 alene eller i kombinasjon med Semaglutid ved fedme
En fase 2a, multisenter, randomisert, dobbeltblind, placebokontrollert studie for å evaluere sikkerheten, tolerabiliteten, farmakokinetikken og farmakodynamikken til VTX3232 alene eller i kombinasjon med Semaglutid hos deltakere med fedme
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35235
- 840005
-
-
California
-
Lake Forest, California, Forente stater, 92630
- 840003
-
Long Beach, California, Forente stater, 90815
- 840011
-
-
Florida
-
Largo, Florida, Forente stater, 33761
- 840001
-
Ocoee, Florida, Forente stater, 34761
- 840012
-
Port Orange, Florida, Forente stater, 32127
- 840016
-
-
Kansas
-
Newton, Kansas, Forente stater, 67114
- 840014
-
-
Louisiana
-
Marrero, Louisiana, Forente stater, 70072
- 840015
-
Marrero, Louisiana, Forente stater, 70072
- 840017
-
-
Texas
-
Austin, Texas, Forente stater, 78705
- 840002
-
Dallas, Texas, Forente stater, 75230
- 840006
-
San Antonio, Texas, Forente stater, 78229
- 840013
-
San Antonio, Texas, Forente stater, 78229
- 840018
-
Waco, Texas, Forente stater, 76710
- 840010
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants are male or female ≥ 18 years up to ≤ 80 years of age.
- Ability to comply with study requirements.
- BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening.
- Stable body weight (± 5%) for at least 3 months prior to screening.
- hs-CRP ≥ 2 mg/L at screening.
- Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy.
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion Criteria:
-
Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity
-
Have any prior diagnosis of diabetes mellitus
-
Current participation (or within the last 3 months) in an organized weight reduction program.
-
History or presence of clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass [bariatric] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity.
-
Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.
-
Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study.
-
Receipt of the following medications:
- Any immunosuppressive biologic or targeted therapy within 90 days prior to Day 1.
- Use of anti-inflammatory medications within 30 days prior to Day 1
- Colchicine within 30 days prior to Day 1.
- Glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Participants received placebo orally once daily for 12 weeks and were followed for 30 days after the last dose. |
Placebo |
|
Eksperimentell: VTX3232 30 mg
Participants received VTX3232 30 milligrams (mg) orally once daily for 12 weeks and were followed for 30 days after the last dose. |
VTX3232 30 mg |
|
Aktiv komparator: Placebo + Semaglutide
Participants received placebo orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose. |
Placebo in combination with semaglutide |
|
Eksperimentell: VTX3232 30 mg + Semaglutide
Participants received VTX3232 30 mg orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose. |
VTX3232 30 mg in combination with semaglutide |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
Tidsramme: From the first dose of study treatment to Week 16
|
A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment. |
From the first dose of study treatment to Week 16
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level
Tidsramme: From baseline to Week 12
|
From baseline to Week 12
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Snehal Naik, PhD, Zomagen Biosciences Ltd.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- VTX3232-204
- J7V-MC-EOBA (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .